These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2474522

  • 1. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 2. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988 Jul; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
    Morote Robles J, de Torres Mateos JA, Soler-Roselló A.
    Actas Urol Esp; 1988 Jul; 12(2):152-7. PubMed ID: 2458015
    [No Abstract] [Full Text] [Related]

  • 5. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985 Jul; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 6. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

  • 7. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Sep; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [New prospective diagnostic serum markers in prostatic cancer].
    Mirone V, De Bellis G, Prezioso D, Sanseverino R, Iannucci F, Padulano P.
    Minerva Med; 1986 Mar 31; 77(13):503-4. PubMed ID: 2422605
    [No Abstract] [Full Text] [Related]

  • 10. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J, de Torres Mateos JA.
    Arch Esp Urol; 1989 Mar 31; 42 Suppl 2():124-30. PubMed ID: 2484148
    [Abstract] [Full Text] [Related]

  • 11. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
    Kuriyama M, Loor R, Wang MC, Lee C, Killian CS, Papsidero LD, Inaji H, Nishiura T, Slack NH, Murphy GP, Chu TM.
    Int Adv Surg Oncol; 1982 Mar 31; 5():29-49. PubMed ID: 6178696
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar 31; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 14. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O, Kontturi M.
    Scand J Urol Nephrol Suppl; 1988 Mar 31; 110():109-12. PubMed ID: 2973121
    [Abstract] [Full Text] [Related]

  • 15. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
    Behrakis P, Koutsilieris M.
    Anticancer Res; 1997 Mar 31; 17(3A):1517-8. PubMed ID: 9179189
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M, Carlström K, Rozell BL, Stege R, Pousette A.
    Clin Cancer Res; 2000 May 31; 6(5):1790-5. PubMed ID: 10815899
    [Abstract] [Full Text] [Related]

  • 17. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
    Khil MS, Kim JH, Bricker LJ, Cerny JC.
    Cancer J Sci Am; 1997 May 31; 3(5):289-96. PubMed ID: 9327153
    [Abstract] [Full Text] [Related]

  • 18. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988 May 31; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 19. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997 May 31; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 20. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma.
    Larson A, Fritjofsson A, Norlén BJ, Gronowitz JS, Ronquist G.
    Scand J Clin Lab Invest Suppl; 1985 May 31; 179():81-8. PubMed ID: 2417306
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.